News

FOLLOW OUR SCIENCE

OUR NEWS

NEWS

  • Press Release

Brenus annouces its international scientific committee.

Read more

NEWS

  • Scientific results

ASCO annual meeting 2023 (HCL, Inovotion, Explicyte, IRCM, CGFL)

Read more

NEWS

  • Scientific results

Poster AACR Annual meeting 2023 (Explicyte, Institut Bergonié)

Read more

NEWS

  • Scientific results

Poster AACR Annual meeting 2023 (Inovotion)

Read more

NEWS

  • Scientific results

Poster SITC Annual Meeting 2022 (CLB, IRCM)

Read more

NEWS

  • Scientific results

Poster SITC annual meeting 2022 (Inovotion)

Read more

NEWS

  • Scientific results

Poster AACR Annual Meeting 2022 (IRCM, Institut Bergonié)

Read more

NEWS

  • Scientific results

Poster AACR annual meeting 2022 (CGFL)

Read more

NEWS

  • Scientific results

AACR Virtual Special Conference 2021

Read more

NEWS

  • Press Release

Brenus annouces its international scientific committee.

Read more

NEWS

  • Scientific results

ASCO annual meeting 2023 (HCL, Inovotion, Explicyte, IRCM, CGFL)

Read more

NEWS

  • Scientific results

Poster AACR Annual meeting 2023 (Explicyte, Institut Bergonié)

Read more

NEWS

  • Scientific results

Poster AACR Annual meeting 2023 (Inovotion)

Read more

NEWS

  • Scientific results

Poster SITC Annual Meeting 2022 (CLB, IRCM)

Read more

NEWS

  • Scientific results

Poster SITC annual meeting 2022 (Inovotion)

Read more

NEWS

  • Scientific results

Poster AACR Annual Meeting 2022 (IRCM, Institut Bergonié)

Read more

NEWS

  • Scientific results

Poster AACR annual meeting 2022 (CGFL)

Read more

NEWS

  • Scientific results

AACR Virtual Special Conference 2021

Read more

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page